Navigation Links
NeurogesX Reports Third Quarter 2009 Results
Date:11/6/2009

ive relationship with Astellas continues and our commercialization partner is working diligently toward a 2010 E.U. launch of Qutenza."

Third Quarter 2009 Financial Results

Collaboration revenue for the third quarter of 2009 was approximately $0.1 million, reflecting the initial amortization of upfront payments in connection with the Astellas Agreement. Commencement of revenue recognition during the three months ended September 30, 2009 was triggered by the completion of the transfer of the E.U. Qutenza MA from NeurogesX to Astellas in late September 2009.

Total operating expenses for the third quarter of 2009 were approximately $6.8 million, up 7.8% from approximately $6.3 million in the same period of 2008. The increase was primarily associated with a $1.2 million sublicense fee to the University of California, recorded as part of research and development expenses. The fee, which is due to be paid in the first quarter of 2010, was triggered in the most recent quarter upon receipt of a component of the upfront payments from Astellas. Excluding the sublicense fee, research and development expenses decreased year-over-year as a result of the Company's efforts to preserve cash resources to support its regulatory submissions processes in both the United States and the European Union and to devote resources to certain pre-commercialization activities. During the third quarter 2009 there was also an increase in general and administrative expenses versus the year ago period, primarily as a result of an increase in non-cash stock based compensation expense and continued focus on preparing for the potential U.S. launch of Qutenza in the United States.

Net loss for the third quarter of 2009 was approximately $6.8 million, compared to a net loss of approximately $6.3 million for the third quarter of 2008. Net loss per share was $0.38 per share and $0.36 per share for the three months ended September 30, 2009 and 2008, respe
'/>"/>

SOURCE NeurogesX
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. NeurogesX to Present at Two November Conferences
2. NeurogesX to Present at UBS Global Life Sciences Conference
3. NeurogesX to Present at Upcoming Fall Conferences
4. NeurogesX Appoints New Board Director and Audit Committee Chairman
5. NeurogesX Reports Second Quarter 2009 Results
6. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
7. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
8. NeurogesX Added to Russell 3000 Index
9. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
10. NeurogesX to Present at Needham Life Sciences Conference
11. NeurogesX Receives European Commission Approval for Qutenza(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/26/2014)... (PRWEB) October 26, 2014 The report ... by Application - Global Trends & Forecast to 2019", ... analysis and forecasting of volume consumed and value generated. ... 4,253.9 KT in 2014 to 6,701.3 KT by 2019, ... , Browse 91 market data tables and 22 figures ...
(Date:10/25/2014)... Los Angeles, California (PRWEB) October 23, 2014 ... VDRM ), a specialty pharmaceutical company devoted to ... pursuing out-licensing partnerships in 2015. , ViaDerma has ... method, which allows for rapid mass transfer of ... into the body to provide immediate localized therapy. ...
(Date:10/25/2014)... October 24, 2014 According to ... by Data Center Types (Colocation, Enterprise, Telecom), by ... (Tier 1, Tier 2, Tier 3, Tier 4) ... defines and segments the Data Center Construction Market ... forecasting of revenues. This research report also identifies ...
(Date:10/25/2014)... Va. (PRWEB) October 24, 2014 ... the nation’s leading nonprofit authority on the ... healthcare information exchange, announces its appointment of four ... Workgroup. The workgroup leaders include:, , ... ,     Erik Pupo, Specialist Leader, Deloitte Consulting ...
Breaking Biology Technology:Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 2Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 3Protective Coatings Market Poised to Reach $18,431.8 Million by 2019 - Report by MarketsandMarkets 4ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 2Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 3Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 4WEDI Appoints Four New Security and Privacy Workgroup Co-chairs 2
... ... Office has announced the launch of several innovative new programs to aid ... The first is aimed at entrepreneurs and offers them the opportunity ... 24 months without requiring any equity in their start-up companies. The ...
... , ROCKAWAY, N.J., Dec. 14 The ... , published by the Infusion Nurses Society ... Anthracyclines are a group of chemotherapy medications including daunorubicin, ... treatment of various types of cancer since the early 1970s.(2) ...
... ... Powder Flow Tester – helping Brookfield move from sheet metal to a plastic enclosure ... ... a US-based thermoforming company, has completed the delivery of Brookfield Engineering’s Powder Flow Tester ...
Cached Biology Technology:The Prinz Law Office Launches Innovative New Programs to Aid Cash-Strapped Entrepreneurs and Businesses 2Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 2Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 3Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 4Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 5Thermofab Helps Brookfield Engineering Move To A Compact Custom Plastic Enclosure 2
(Date:10/29/2014)... Online registration is open for the ... Scientific Meeting. SIR 2015 is the one ... trainees and related health care professionals can ... image-guided science and technologies being presented, discussed ... community in minimally invasive, image-guided medicine, SIR ...
(Date:10/29/2014)... household and industrial products are in the environment – ... of them, scientists have yet to determine whether they ... toward doing that by estimating which substances people are ... in the ACS journal Environmental Science & Technology ... the risks to human health of any given substance ...
(Date:10/29/2014)... LANSING, Mich. – As bodies decompose, their types ... the clues they provide could mean the difference ... , Michigan State University is using a more ... help Detroit death-scene investigators examine these changing populations. ... as geographical location of death, gender, race, socioeconomic ...
Breaking Biology News(10 mins):SIR 2015: Interventional radiology shapes tomorrow's medicine 2MSU partners with Detroit to investigate death scenes 2
... FL, January 13, 2014 Scientists from the Florida campus ... of drug candidates that advance the search for new treatments ... drug scaffolds, described in a recent edition of The ... act on a demonstrated therapeutic target, the kappa opioid receptor ...
... have devised a way to measure the mass of ... one millionth of a trillionth of a gram. Weighing ... components of cells, could help researchers better understand their ... technology previously developed by Scott Manalis, an MIT professor ...
... say they practice some form of yoga and/or meditation. ... these practices seems unknown or elusive to many practitioners ... during meditation practice , by Fred Travis, PhD, Director ... at Maharishi University of Management, provides an overview ...
Cached Biology News:Scientists develop promising drug candidates for pain, addiction 2Weighing particles at the attogram scale 2Weighing particles at the attogram scale 3Weighing particles at the attogram scale 4Transcendental experiences during meditation 2Transcendental experiences during meditation 3
...
... Dyad instrument is the most advanced thermal ... world-class thermal performance, the Dyad also boasts ... as point-and-click navigation via touch pad or ... easily and economically expanded to a four-bay ...
...
Kit for testing the ability of a compound to simulate lipolysis in cultured human adipocytes. Kit contains controls, buffers and reagents for detecting glycerol and non-esterified free fatty acids. A...
Biology Products: